Premium
Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones
Author(s) -
Bernhard Helga,
Karbach Julia,
Wölfel Thomas,
Busch Petra,
Störkel Stefan,
Stöckle Michael,
Wölfel Catherine,
Seliger Barbara,
Huber Christoph,
Zum Büschenfelde KarlHermann Meyer,
Knuth Alexander
Publication year - 1994
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910590621
Subject(s) - ctl* , cytotoxic t cell , antigen , immunology , clone (java method) , human leukocyte antigen , biology , cd8 , t lymphocyte , monoclonal antibody , immunotherapy , immune system , cancer research , antibody , in vitro , dna , biochemistry , genetics
Cytotoxic T lymphocyte (CTL) clones directed against autologous renal‐cell carcinoma (RCC) cell lines were generated by mixed lymphocyte/tumor‐cell culture (MLTC) using peripheral blood lymphocytes (PBL). A CD8+, CD4‐ CTL clone MZ1257‐CTL 5/30 with high cytolytic activity for the autologous tumor cell line MZ1257‐RCC was established. No lysis of the autologous EBV‐transformed B lymphocytes (EBV‐B) or K562 cells was observed. A panel of HLA‐A2‐matched allogeneic RCC lines was recognized by CTL 5/30. Further specificity analysis showed a cross‐reactivity with HLA‐A2‐matched allogeneic tumor cells of various origins, especially melanoma. CTL 5/30 was also cross‐reactive with several HLA‐A2‐positive allogeneic normal kidney cells in culture. The restriction element identified for CTL 5/30 was HLA‐A2, as shown by blocking of cytotoxicity using an anti‐HLA‐A2 monoclonal antibody (MAb) and by resistance of an HLA‐A2‐negative melanoma variant SK29‐MEL. 1.22 against lysis by CTL 5/30. In this report we demonstrate HLA‐A2‐restricted recognition of a T‐cell‐defined antigen on autologous renal‐cancer cells. This antigen is also expressed and recognized in association with HLA‐A2 on normal kidney cells in culture and other HLA‐A2‐positive tumor cells. It may therefore be a normal differentiation antigen to which tolerance is incomplete in the renal‐cell cancer system investigated.